THE COMPOUND 5-ethyl-5-(2-methylallyl)-2-thiobarbituric acid (called for experimental purposes V-121) was prepared by Abbott Laboratories during the synthesis of a series of barbituric acid derivatives and was found to exhibit high efficiency as a motion sickness preventive (Noble2) in association with low hypnotic power. It seemed possible, therefore, that the drug might be effective in controlling the attacks of vertigo in cases of Ménière's syndrome, and an investigation was undertaken to determine this point.
MATERIAL AND PROCEDURE
Type of Case Investigated.—The acute attack in cases of Ménière's syndrome is of two types: (1) a sudden, severe attack of rotational vertigo, occurring without warning and followed, after a short interval, by vomiting; (2) a more gradual attack of less severity and longer duration, accompanied with nausea but seldom with actual vomiting, characterized by gross disturbance of balance without the sensation of rotation and often initiated by change of position—thus being more akin
ATKINSON M. MÉNIÈRE'S SYNDROME: A New Drug for Control of the Acute Attack. Arch Otolaryngol. 1950;51(3):312–315. doi:10.1001/archotol.1950.00700020334002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.